Abstract
Germline mutations in genes involved in homologous recombination repair (HRR) represent a new target for various cancers. PARP (Poly-ADP-Ribose-Phosphate) inhibitors have been approved in prostate, pancreatic, breast, and ovarian cancers for patients with such mutations. These mutations are present in 5 to 10% of patients with lung cancer but have not been shown to be causal in the development of NSCLC and are not currently targetable as in other cancer types. At our hospital, we have noted that patients with stage IV oncogene-driven NSCLC and incidentally found germline HRR mutations appear to progress through first-line therapy more quickly compared with patients with oncogene-driven NSCLC without germline HRR mutations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
